Linked Data API

Show Search Form

Search Results

100022
star this property registered interest false more like this
star this property date less than 2014-10-15more like thismore than 2014-10-15
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Patient Choice Schemes more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what steps he is taking to promote patient choice. more like this
star this property tabling member constituency Stroud more like this
star this property tabling member printed
Neil Carmichael more like this
unstar this property uin 905559 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2014-10-21more like thismore than 2014-10-21
star this property answer text <p>We are committed to patients having greater choice and control over their healthcare, as this can help drive up standards and improve patient care.</p><p> </p><p> </p><p> </p><p>We believe that patient empowerment is vital to the National Health Service in the 21st century. This Government is committed to continuing to develop digital platforms to enable this to happen, such as My NHS and the NHS e-Referral Service.</p><p> </p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property question first answered
less than 2014-10-21T16:00:56.1397924Zmore like thismore than 2014-10-21T16:00:56.1397924Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
4104
unstar this property label Biography information for Neil Carmichael more like this
100402
star this property registered interest false more like this
star this property date less than 2014-10-22more like thismore than 2014-10-22
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Paralysis more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what steps he has taken to support University College London in its work to enable people who have been paralysed to regain the ability to walk. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
unstar this property uin 211576 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2014-10-27more like thismore than 2014-10-27
star this property answer text <p>The Department’s National Institute for Health Research (NIHR) funds 11 biomedical research centres that conduct translational research to transform scientific breakthroughs into benefits for patients. These centres are formed through partnerships between England’s leading National Health Service organisations and universities.</p><p> </p><p> </p><p> </p><p>The NIHR is investing £110 million over five years (2012-17) in the NIHR biomedical research centre at University College London Hospitals NHS Foundation Trust and University College London. The centre is supporting research on the use of cells from the lining of the nose to repair damaged nerves in the spinal cord.</p><p> </p><p><strong> </strong></p><p> </p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property question first answered
less than 2014-10-27T16:53:22.0851128Zmore like thismore than 2014-10-27T16:53:22.0851128Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
4131
unstar this property label Biography information for Jim Shannon more like this
100411
star this property registered interest false more like this
star this property date less than 2014-10-22more like thismore than 2014-10-22
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Cystic Fibrosis more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what steps the Government is taking to support research into new treatments for people with cystic fibrosis. more like this
star this property tabling member constituency Barnsley Central more like this
star this property tabling member printed
Dan Jarvis more like this
unstar this property uin 211584 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2014-10-27more like thismore than 2014-10-27
star this property answer text <p>The National Institute for Health Research (NIHR) Evaluation, Trials and Studies Coordinating Centre manages the Efficacy and Mechanism Evaluation programme. With funding from the Medical Research Council, this programme is currently supporting a £3.3 million trial of repeated application of gene therapy in patients with cystic fibrosis. The report of this trial is expected to be published in August 2015.</p><p> </p><p><strong> </strong></p><p> </p><p>A range of commercial and researcher-led cystic fibrosis treatment trials and studies are hosted by NIHR research infrastructure including the NIHR Clinical Research Network, NIHR biomedical research centres and units, and NIHR clinical research facilities for experimental medicine.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property question first answered
less than 2014-10-27T16:52:12.8962611Zmore like thismore than 2014-10-27T16:52:12.8962611Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
4243
unstar this property label Biography information for Dan Jarvis more like this
100816
star this property registered interest false more like this
star this property date less than 2014-10-23more like thismore than 2014-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Terminal Illnesses more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what guidance his Department has issued to health technology appraisal committees on application of NICE's end of life criteria when appraising treatments for patients with terminal illness. more like this
star this property tabling member constituency Redcar more like this
star this property tabling member printed
Ian Swales more like this
unstar this property uin 211809 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove maximum value filtermore like thismore than 2014-10-28
star this property answer text <p>The Department has not issued any such guidance. The National Institute for Health and Care Excellence is an independent body and is responsible for the development of its methods and processes.</p><p> </p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property question first answered
less than 2014-10-28T14:56:20.6436753Zmore like thismore than 2014-10-28T14:56:20.6436753Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
4045
unstar this property label Biography information for Ian Swales more like this
100817
star this property registered interest false more like this
star this property date less than 2014-10-23more like thismore than 2014-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Terminal Illnesses more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what rationale lies behind NICE's advice that end-of-life criteria should only apply to medicines that extend life by at least three months. more like this
star this property tabling member constituency Redcar more like this
star this property tabling member printed
Ian Swales more like this
unstar this property uin 211807 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove maximum value filtermore like thismore than 2014-10-28
star this property answer text <p>In January 2009, the National Institute for Health and Care Excellence (NICE) issued supplementary advice to its appraisal committees on appraising treatments which may be life-extending for patients, with short life expectancy, and which are licensed for indications affecting small numbers of patients with incurable illnesses.</p><p> </p><p> </p><p> </p><p>This sets out the following three criteria that must all be satisfied for this supplementary advice to be applied:</p><p> </p><p>- the treatment is indicated for patients with a short life expectancy, normally less than 24 months;</p><p> </p><p>- there is sufficient evidence to indicate that the treatment offers an extension to life, normally of at least an additional three months, compared to current NHS treatment; and</p><p> </p><p>- the treatment is licensed or otherwise indicated, for small patient populations.</p><p> </p><p> </p><p> </p><p>These criteria were developed following public consultation and set out the circumstances when NICE considers it is appropriate for its appraisal committees to apply greater flexibility in their appraisal of these treatments.</p><p> </p><p> </p><p> </p><p>The advice has now been incorporated chapter 6 of <em>Guide to the methods of technology appraisal 2013 </em>which can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/article/pmg9/chapter/6-the-appraisal-of-the-evidence-and-structured-decision-making" target="_blank">www.nice.org.uk/article/pmg9/chapter/6-the-appraisal-of-the-evidence-and-structured-decision-making</a></p><p> </p><p> </p><p> </p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property question first answered
less than 2014-10-28T14:27:08.2752956Zmore like thismore than 2014-10-28T14:27:08.2752956Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
4045
unstar this property label Biography information for Ian Swales more like this
65962
star this property registered interest false more like this
star this property date less than 2014-07-07more like thismore than 2014-07-07
star this property answering body
Department for Business, Innovation and Skills more like this
star this property answering dept id 26 more like this
star this property answering dept short name Business, Innovation and Skills more like this
star this property answering dept sort name Business, Innovation and Skills more like this
star this property hansard heading Life Sciences: Northern Ireland more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Business, Innovation and Skills, what work the Life Science Investment Organisation is doing to promote the life sciences sector in Northern Ireland. more like this
star this property tabling member constituency Bury South more like this
star this property tabling member printed
Mr Ivan Lewis more like this
unstar this property uin 204143 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2014-07-22more like thismore than 2014-07-22
star this property answer text <p>The Life Sciences Organisation (LSO) (previously the Life Sciences Investment Organisation, which now includes responsibility for UK trade promotion) works to promote the UK Life Sciences sector as a whole. LSO works closely with Invest Northern Ireland, along with the other devolved bodies and local enterprise partnerships across England, to understand the nation’s internationally competitive commercial offers in life sciences. We then actively market these strengths using our international network of investment advisors and suite of promotional materials. Where potential investors have specifically stated particular requirements, we will match these to the various regional offers and bring these out clearly in the tailored proposition materials produced for the investors.</p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property question first answered
less than 2014-07-22T14:48:34.7611172Zmore like thismore than 2014-07-22T14:48:34.7611172Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
441
unstar this property label Biography information for Mr Ivan Lewis more like this
77653
star this property registered interest false more like this
star this property date less than 2014-07-14more like thismore than 2014-07-14
star this property answering body
Department for Business, Innovation and Skills more like this
star this property answering dept id 26 more like this
star this property answering dept short name Business, Innovation and Skills more like this
star this property answering dept sort name Business, Innovation and Skills more like this
star this property hansard heading Manufacturing Industries: Drugs more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Business, Innovation and Skills, what steps his Department is taking to encourage international pharmaceutical companies to locate in the UK. more like this
star this property tabling member constituency Salisbury more like this
star this property tabling member printed
John Glen more like this
unstar this property uin 205633 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2014-08-28more like thismore than 2014-08-28
star this property answer text <p>In December 2011, the Government launched the Strategy for UK Life Sciences which includes measures to improve the commercial, research and regulatory environment, with the aim of making the UK the location of choice for investment. Government has also taken steps to strengthen protection for intellectual property in the UK.</p><p>In 2012 a specific organisation was set up to promote life sciences to international companies: the Life Sciences Investment Organisation (now reformed as the Life Sciences Organisation (LSO), with responsibility also for UK trade promotion). LSO collects and distils information on the UK’s internationally competitive commercial offers in life sciences; these are marketed to potential investors via the UK Trade and Investment global network of investment advisors, with tailored support provided to those investors that choose the UK.</p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property question first answered
less than 2014-08-28T15:54:58.4454504Zmore like thismore than 2014-08-28T15:54:58.4454504Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
4051
unstar this property label Biography information for John Glen more like this
78736
star this property registered interest false more like this
star this property date less than 2014-07-17more like thismore than 2014-07-17
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Meningitis: Vaccination more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, whether the Bexsero vaccine is licensed for (a) individual application and (b) use in conjunction with other vaccines. more like this
star this property tabling member constituency The Cotswolds more like this
star this property tabling member printed
Geoffrey Clifton-Brown more like this
unstar this property uin 206537 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2014-09-02more like thismore than 2014-09-02
star this property answer text <p>Bexsero, a Meningococcal group B vaccine, was licenced for the active immunisation of individuals from two months of age and older against invasive meningococcal disease caused by <em>Neisseria meningitidis</em> group B. It can be administered individually or concomitantly with a number of other vaccine antigens, either as monovalent or as combination vaccines such as diphtheria, tetanus, acellular pertussis, <em>Haemophilus influenzae </em> type b, inactivated poliomyelitis, hepatitis B, heptavalent pneumococcal conjugate, measles, mumps, rubella, and varicella. When given concomitantly with other vaccines Bexsero must be administered at a separate injection site.</p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property question first answered
less than 2014-09-02T13:40:37.255071Zmore like thismore than 2014-09-02T13:40:37.255071Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
249
unstar this property label Biography information for Sir Geoffrey Clifton-Brown more like this
78909
star this property registered interest false more like this
star this property date less than 2014-07-18more like thismore than 2014-07-18
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Parkinson's Disease more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, how many incidents of medication errors involving hospital patients with Parkinson's disease have been reported since the joint patient safety alert on steps to improve data reporting quality was issued by NHS England and the Medicines and Healthcare Products Regulatory Agency in March 2014. more like this
star this property tabling member constituency Newcastle upon Tyne North more like this
star this property tabling member printed
Catherine McKinnell more like this
unstar this property uin 206600 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2014-09-03more like thismore than 2014-09-03
star this property answer text <p>NHS England has advised that, between 20 March 2014 and 21 July 2014, 617 incidents in general, acute or community hospitals or mental health facilities involving Parkinson’s disease and medicines used to treat Parkinson’s disease were reported through the National Reporting and Learning System.</p><p>Improving services for people with Parkinson's disease and other neurological conditions is a key priority for NHS England. Its strategic clinical networks have a specific focus on patients with neurological problems, such as Parkinson’s disease. NHS trusts and care homes in England should have policies and procedures in place to ensure that people with Parkinson’s disease receive their medicines when they are required to take them to control their illness and symptoms.</p><p>NHS England has recently launched a medication ‘safety thermometer’ that enables health and care organisations to measure aspects of medication safety on a regular basis for improvement purposes. This will enable hospitals to track their progress in reducing the number of omitted doses of medicines, including of those used to treat Parkinson’s disease.</p><p> </p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property grouped question UIN 206629 more like this
star this property question first answered
less than 2014-09-03T09:44:33.9915993Zmore like thismore than 2014-09-03T09:44:33.9915993Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
4125
unstar this property label Biography information for Catherine McKinnell more like this
78911
star this property registered interest false more like this
star this property date less than 2014-07-18more like thismore than 2014-07-18
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Parkinson's Disease more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, with reference to the National Patient Safety Agency rapid response report on reducing harm from omitted and delayed medicines in hospital, what steps his Department has taken to ensure that hospitals in England and Wales are able to supply Parkinson's disease medications to patients in a timely way. more like this
star this property tabling member constituency Newcastle upon Tyne North more like this
star this property tabling member printed
Catherine McKinnell more like this
unstar this property uin 206629 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2014-09-03more like thismore than 2014-09-03
star this property answer text <p>NHS England has advised that, between 20 March 2014 and 21 July 2014, 617 incidents in general, acute or community hospitals or mental health facilities involving Parkinson’s disease and medicines used to treat Parkinson’s disease were reported through the National Reporting and Learning System.</p><p>Improving services for people with Parkinson's disease and other neurological conditions is a key priority for NHS England. Its strategic clinical networks have a specific focus on patients with neurological problems, such as Parkinson’s disease. NHS trusts and care homes in England should have policies and procedures in place to ensure that people with Parkinson’s disease receive their medicines when they are required to take them to control their illness and symptoms.</p><p>NHS England has recently launched a medication ‘safety thermometer’ that enables health and care organisations to measure aspects of medication safety on a regular basis for improvement purposes. This will enable hospitals to track their progress in reducing the number of omitted doses of medicines, including of those used to treat Parkinson’s disease.</p><p> </p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property grouped question UIN 206600 more like this
star this property question first answered
less than 2014-09-03T09:44:34.1195901Zmore like thismore than 2014-09-03T09:44:34.1195901Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
4125
unstar this property label Biography information for Catherine McKinnell more like this